Drugs / SAR441000
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03871348 | Jan 2019 → Jul 2022 | metastatic neoplasm | Sanofi | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-14 | BioNTech SE | BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting biontech.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR441000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03871348 ↗ |
| Modality | Messenger RNA (mRNA) | “SAR441000 (mixture of four mRNAs encoding IL-12, single-chain IFN-α-2b, GM-CSF, and IL-15 sushi domain)” PMID 40152791 ↗ Jun 2025 |